Dissemin is shutting down on January 1st, 2025

Published in

SAGE Publications, Journal of Intellectual Disabilities, 1(26), p. 137-148, 2020

DOI: 10.1177/1744629520961958

Links

Tools

Export citation

Search in Google Scholar

Factors contributing to antihypertensive medication adherence among adults with intellectual and developmental disability

Journal article published in 2020 by Nicholas V. Resciniti ORCID, Yuan Hong, Suzanne McDermott
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Adults with intellectual or developmental disabilities often have hypertension and mental illness, and are prescribed medications for treatment. This study examined psychotropic medication adherence as a mediator between the association of residence type and antihypertensive medication adherence for adults with intellectual or developmental disabilities. We used Medicaid data of adults with intellectual or developmental disabilities who had hypertension and prescribed antihypertensive medication (N = 1,201) to measure the direct effect, indirect effect, and total effect of residence type (home vs. supervised setting) and antihypertensive medication adherence, with a mediator of psychotropic medication adherence. The indirect effect of psychotropic medication adherence on antihypertensive medication adherence was 1.26 (OR = 1.26, CI: 1.08–1.52), holding residency constant. The direct effect of residential type on antihypertensive medication adherence was 3.75 (OR = 3.75, CI: 1.61–8.75). This association may be due to some features of having a mental illness or maybe the result of being prescribed more than one medication.